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Introduction: Cupping is used in various traditional medicine forms to relieve pain in musculoskeletal diseases.
The aim of this study was to investigate the effectiveness of cupping in relieving the symptoms of knee
osteoarthritis (OA).
Methods: In a two-group, randomized controlled exploratory pilot study patients with a clinically and radiological
confirmed knee OA (Kellgren-Lawrence Grading Scale: 2-4) and a pain intensity > 40 mm on a 100 mm visual
analogue scale (VAS) were included. 40 Patients were randomized to either 8 sessions of pulsatile dry cupping
within 4 weeks or no intervention (control). Paracetamol was allowed on demand for both groups. Outcomes were
the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) score, the pain intensity on a VAS
(0 mm = no pain to 100 mm =maximum intensity) and Quality of Life (SF-36) 4 and 12 weeks after randomization.
Use of Paracetamol was documented within the 4-week treatment period. Analyses were performed by analysis of
covariance adjusting for the baseline value for each outcome.
Results: 21 patients were allocated to the cupping group (5 male; mean age 68 ± SD 7.2) and 19 to the control
group (8 male; 69 ± 6.8). After 4 weeks the WOMAC global score improved significantly more in the cupping group
with a mean of 27.7 (95% confidence interval 22.1; 33.3) compared to 42.2 (36.3; 48.1) in the control group
(p = 0.001). After 12 weeks the WOMAC global score were still significantly different in favor for cupping (31.0 (24.9;
37.2) vs. 40.8 (34.4; 47.3) p = 0.032), however the WOMAC subscores for pain and stiffness were not significant
anymore. Significantly better outcomes in the cupping group were also observed for pain intensity on VAS and for
the SF-36 Physical Component Scale compared to the control group after 4 and 12 weeks. No significant difference
was observed for the SF-36 Mental Component Scale and the total number of consumed Paracetamol tablets
between both groups (mean 9.1, SD ± 20.0 vs. 11.5 ± 15.9).
Conclusion: In this exploratory study dry cupping with a pulsatile cupping device relieved symptoms of knee OA
compared to no intervention. Further studies comparing cupping with active treatments are needed.
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Osteoarthritis (OA) is a clinical syndrome of joint pain
accompanied by varying degrees of functional limitation
and reduced quality of life. It is one of the leading causes
of pain and disability worldwide [1]. Pathological
changes include localized loss of articular cartilage and
new bone formation in places of destructive bone loss at
joint margins [1]. The most common location for OA is
the knee joint, followed by the feet and hips, and it
becomes more common with age and women are more
affected than men [2]. The treatment focuses on the re-
duction of pain and stiffness, and the maintenance or
improvement of join function; further aims of treat-
ments are the delay of the progression of joint damage
and improving the patient’s quality of life [3]. Pharmaco-
logical treatments include anti-inflammatory medica-
tions such as nonsteroidal anti-inflammatory drugs,
which are frequently used to treat the symptoms and are
frequently associated with side effects [2,3]. Because oral
medication often does not lead to an adequate clinical
response in OA, non-pharmacological therapies such as
exercise, weight reduction, and physical therapies play
an important role in the long-term management of
osteoarthritis and are recommended in guidelines. In
addition, complementary and alternative medicine
(CAM) treatments such as acupuncture or herbal medi-
cine are used frequently by OA patients.
Cupping is one of the oldest known medical therapies.
The first descriptions of cupping in the west date back
to the famous Egyptian “Ebers Papyrus” (1550 BC) and
it was also used in ancient Greek medicine [4]. In
addition, cupping is used in traditional Asian medical
systems such as Ayurveda, Chinese, Tibetan and Orien-
tal Medicine. In Europe it was widely taught and used
from medieval times by monastery treatment providers
up to the 19th century by physicians. Throughout the
centuries, it was also commonly used by folk healers and
laymen but also by medical doctors. It was not until re-
cently, in the 20th century following the development of
modern pharmaceuticals, that cupping more or less van-
ished from mainstream western medicine. Today it is
primarily practiced by naturopaths and other CAM
treatment providers. Cupping is used for a wide range of
diseases. In ancient Greece, Hippocratic physicians
recommended it for the treatment of musculoskeletal
diseases of the back and extremities, gynecological com-
plaints, pharyngitis, ear ailments and lung diseases [4].
From the therapeutic-principle perspective cupping is a
sucking method [5]. The cupping glass is applied to a
predefined skin area of the body and a vacuum is gener-
ated by mechanically withdrawing or thermally cooling
the trapped air under the cup. The skin is then sucked
into the cupping glass, resulting in a reddening and
warming of the affected area due to increased perfusion.When the vacuum is strong, signs of sub- and/or intra-
cutaneous bleeding (petechiae) may appear. There are
two general forms of cupping: dry and wet cupping. In
dry cupping only the vacuum is applied; in wet cupping,
the skin under the cups is pricked with needles or a scal-
pel and the blood is sucked into the cup. Pulsatile cup-
ping is a modernized technology using a mechanical
device that generates a pulsatile vacuum with a pump.
Traditionally cups made of glass, metals or even bamboo
are used for cupping, but they do not allow the complete
cupping of a big joint, like the knee. Today flexible sili-
cone cups allow a complete cupping also of big joints.
Although cupping has a long tradition there is only
limited evidence of its effectiveness. However, recent
clinical studies have reported positive results of cupping
in patients with musculoskeletal diseases e.g. lower back
pain [6], carpal tunnel syndrome [7], brachialgia par-
esthetica nocturna [8], cancer pain [9] and chronic neck
pain [10-12]. In China Cupping is widely used and two
systematic reviews were recently published about the
results [13,14].
To date no clinical studies have been published about
the effectiveness of cupping in knee OA. Thus, the aim
of this exploratory study was to investigate the effective-
ness of pulsatile cupping in relieving pain and stiffness
and improving quality of life in patients with osteoarth-
ritis of the knee compared to no intervention.
Methods
Design
This study was designed as a two-group, parallel, rando-
mized controlled, exploratory, clinical study. All study
participants gave their informed consent before inclu-
sion. The study was carried out at two study centers: the
Charité Outpatient Department and in an ambulatory
surgical clinic. Patients were recruited through news-
paper advertisements in Berlin daily newspapers. Study
information and pre-screening was undertaken by phone
by an experienced study nurse. Patients fulfilling the pre-
screening criteria were invited for a personal consult-
ation with the study physician for information, informed
consent, inclusion or exclusion as a study participant,
and baseline assessment. Patients were allocated to treat-
ments groups by simple randomization with a 1:1 ratio
via a central telephone randomization process. The
random allocation sequence was generated by our
statistician using SAS 9.2 software (SAS Institute Inc.
Cary, NC, USA). Patients were enrolled by the study
physician. After signing informed consent and including
the patient in the trial an independent study nurse on
the telephone line centrally assigned patients to inter-
vention or control according to the randomization list,
allocation was concealed. The study protocol was
reviewed and approved by the Ethics Committee of the
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(EA1/230/09; 11.12.2009). The study was registered at
ClinicalTrials.gov (NCT01057043).Patients
Patients inclusion criteria were: Male and female
patients between 40 and 80 years with osteoarthritis of
the knee according to ACR criteria (American College of
Rheumatology) [15], X-ray classification: Kellgren-
Lawrence Grading Scale: 2 – 4 [16,17], and subjective
pain intensity at baseline > 40 mm on the visual analogue
scale and no other OA therapy except NSAID in the
previous 4 weeks. Patients were excluded if they fulfilled
one or more of the following criteria: current use of
anticoagulants (e.g., Phenprocoumon, Heparin), coagulo-
pathy, or any form of cupping therapy in the previous
12 months; intra-articular injection of corticosteroids or
NSAID into the knee joint in the previous 4 months;
arthroscopy of the knee joint in the previous 12 months,
use of systemic corticosteroids in the previous 4 weeks;
physical therapy, leeches or acupuncture in the previous
4 months or other CAM therapies for osteoarthritis in
the previous 4 weeks.Study interventions
The intervention protocol was developed a priori by a
panel of experienced cupping experts. Patients rando-
mized to the intervention group received 8 sessions of
pulsatile dry cupping within 4 weeks, twice per week. In
addition to cupping the knee, the experts recommended
cupping the lumbosacral area in the same treatment ses-
sion. The traditional cupping experts argued that from
their clinical experience this might increase the total ef-
fect, but they had no theoretical explanation. They
recommended a frequency of 8 sessions in 4 weeks. Pul-
satile cupping was administered by a mechanical cup-
ping device (PRV02, HeVaTec® GmbH) with flexible
silicone cups to the knee joint and plastic glasses to the
skin of the lower back region. The silicone cups allow
the cupping of a complete knee joint. The device gener-
ates a pulsatile vacuum with a pump. The silicone cups
treatment was started with a cupping of the lower back
area with 2 cups on each side for 5 minutes, followed by
cupping the entire affected knee with a big adaptable
silicone cup for 10 minutes (vacuum: 100 – 200 mbar,
interval: 2 seconds, pulse: 30-50%) (Figure 1). The cup-
ping device was never tested in a randomized controlled
trial before.
Patients randomized to the control group received no
cupping intervention for the duration of the study
(12 weeks). Patients in both groups were allowed to take
Paracetamol on demand with a maximum dosage of 2 g/
day according to the NICE guidelines [1] for 4 weeks. Allcontrol-group patients were offered a free complete cup-
ping treatment of 8 sessions after the trial was terminated.
Data collection and outcome parameter
All patients completed standardized questionnaires in-
cluding all outcomes at baseline, and after 4 and
12 weeks. In cases of bilateral osteoarthritis, the knee
defined as more painful at baseline was the one assessed
throughout the entire study. The Western Ontario and
McMasters Universities Osteoarthritis Index (WOMAC)
[18-20] was used to assess pain, stiffness, and physical
functioning (higher scores indicate worse symptoms).
Pain intensity was measured on a visual analogue scale
(VAS) (0 = no pain to 10 =maximum intensity). Generic
Quality of Life (QoL) was measured using the SF-36
questionnaire (higher scores indicate higher QoL) [21].
All patients allocated to the intervention group were
asked to rate the clinical effect after 12 weeks (improved,
not changed, aggravated). As this was an exploratory
pilot study, no outcome was defined as the primary out-
come. The use of Paracetamol was documented by
patients in a diary during the first 4 weeks of the treat-
ment period. Any adverse and serious adverse events
were monitored throughout the study by the physicians
and the patients.
Statistical analysis
Due to the exploratory design of the study, no single pri-
mary outcome was defined and no formal sample-size
calculation was performed. A decision to include 40
patients (about 20 per treatment arm) seemed feasible
(organization, funding) in this setting.
The analyses of WOMAC scores, pain (VAS), and SF-
36 scales after 4 and 12 weeks were performed by
analysis of covariance (ANCOVA) adjusting for the re-
spective baseline value on the intention-to-treat popula-
tion. Adjusted means with 95% confidence intervals (CI)
are presented. Resulting p-values for treatment-group
effects are considered explorative. For the use of Para-
cetamol, descriptive measures (mean, standard deviation
(SD)) are given.
All analyses were performed in SAS 9.2 (SAS Institute
Inc. Cary, NC, USA).
Results
Patients were recruited between January and July 2010.
Treatment and follow-ups of the patients were com-
pleted by March 2011. Altogether 353 patients were
screened for eligibility, 313 of which were not included
(main reasons: knee pain due to other diagnoses, severity
of osteoarthritis not meeting inclusion criteria) (Figure 2).
Of the 40 randomized patients, 21 were allocated to the
cupping group and 19 to the control group. The mean
age of the patients was 68.1 ± 7.2 in the cupping- and
Figure 1 Application of the adaptable silicone cup at the knee.
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sity on the visual analogue scale in both groups was gen-
erally high with mean values of about 60 mm in both
groups. Only small differences between the groups were
found: There were fewer male patients in the cupping
group (n = 5, 23.8%) than in the control group (n = 8,
42.1%), the Quality of Life SF 36 mental component
scale was higher in the cupping group (58.2 ± 7.2) than
in the control group (51.1 ± 11.1) and the WOMACFigure 2 Trial flow chart.stiffness subscore was lower in the cupping group
(43.1 ± 26.9) than in the control group (50.3 ± 22.3).
After 4 weeks the adjusted mean of the WOMAC
global score was 27.7 (95%-confidence interval 22.1;
33.3) in the cupping group which was significant better
(p = 0.001) than for the control group, which had a score
of 42.2 (36.3; 48.1). After 12 weeks, the WOMAC global
score was still significantly better (p = 0.032) in the cup-
ping group (31.0 (24.9; 37.2)) compared to the control
group (40.8 (34.4; 47.3)) (Table 2, Figure 3). In addition,
the WOMAC subscores for pain, stiffness and physical
function showed significantly better outcomes in the
cupping group after 4 weeks, but not for pain and stiff-
ness after 12 weeks (Table 2). Significantly lower pain in-
tensity on the VAS was observed in the cupping group
after 4 weeks (38.4 (30.5; 46.2)) vs. 55.0 (46.8; 63.2) in
the control group (p = 0.005), and after 12 weeks (41.0
(30.7; 51.4) versus 57.2 (46.3; 68.0), respectively, p = 0.036)
(Table 2, Figure 4).
The SF-36 Physical Component Scale was significant
better (p = 0.030), in the cupping group (36.0 (33.5; 38.6)
compared to the control group (31.9 (29.2; 34.6) after
4 weeks, and also after 12 weeks 36.3 (32.9; 39.8) versus
30.2 (26.6; 33.9), respectively (p = 0.019) (Table 2,
Figure 5). In contrast no significant group difference was
observed for the SF-36 Mental Component Scale after
Table 1 Baseline characteristics of patients in both study
groups (values are means and standard deviations except
for gender (n, %))
Characteristics Cupping Control
(n = 21) (n = 19)
Age 68.1 ± 7.2 69.3 ± 6.8
Gender (Male; n (%)) 5 (23.8) 8 (42.1)
BMI 29.0 ± 4.6 28.1 ± 5.5
VAS Pain 60.2 ± 12.2 57.9 ± 8.0
WOMAC
- Global Score 39.1 ± 16.2 41.7 ± 15.2
- Pain Subscore 37.4 ± 17.3 40.2 ± 15.3
- Stiffness Subscore 43.1 ± 26.9 50.3 ± 22.3
- Physical Function Subscore 39.1 ± 17.2 41.1 ± 16.6
SF-36
- Physical Component Scale 30.6 ± 8.5 32.2 ± 8.9
- Mental Component Scale 58.2 ± 7.2 51.1 ± 11.1
BMI = Body Mass Index, WOMAC = Western Ontario and McMasters
Universities Osteoarthritis Index (higher scores indicate worse condition),
VAS = Visual Analogue Scale (0 mm = no pain to 100 mm =maximum
intensity), SF 36 = The Short Form (36) Health Survey (higher scores indicate
higher QoL).
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56.6); p = 0.233) and 12 weeks (cupping: 53.2 (49.5;
56.9), control: 52.6 (48.7; 56.5); p = 0.831) (Table 2,
Figure 6).
Patients’ pain medication intake was low and compar-
able in both groups. Patients in the cupping group docu-
mented a mean intake of 9.1 (SD ± 20.0) ParacetamolTable 2 Outcome measures at 4 weeks and 12 weeks (adjuste
respective baseline value)
Outcomes Cupping (n = 2
Mean (95% CI)
At 4 weeks
WOMAC Global Score 27.7 (22.1; 33.3)
- WOMAC Pain Subscore 25.8 (19.3; 32.3)
- WOMAC Stiffness Subscore 37.2 (28.6; 45.8)
- WOMAC Physical Function Subscore 27.0 (21.4; 32.6)
VAS Pain 38.4 (30.5; 46.2)
SF 36 - Physical Component Scale 36.0 (33.5; 38.6)
SF 36 - Mental Component Scale 56.0 (52.3; 59.7)
At 12 weeks
WOMAC Global Score 31.0 (24.9; 37.2)
- WOMAC Pain Subscore 30.4 (22.5; 38.4)
- WOMAC Stiffness Subscore 36.3 (28.4; 44.2)
- WOMAC Physical Function Subscore 30.4 (24.3; 36.6)
VAS Pain 41.0 (30.7; 51.4)
SF 36 - Physical Component Scale 36.3 (32.9; 39.8)
SF 36 - Mental Component Scale 53.2 (49.5; 56.9)
WOMAC = Western Ontario and McMasters Universities Osteoarthritis Index (higher
to 100 mm =maximum intensity), SF 36 = The Short Form (36) Health Survey (Genetablets compared to 11.5 (± 15.9) tablets in the control
group in the first 4 weeks.
After 12 weeks 10 patients (47.6%) in the cupping
group (n = 21) rated the self observed clinical effect as
“improved”, 8 patients as “not changed” (38.1%) and 3
patients as “aggravated” (14.3%).
No serious adverse events were observed during the
study. Adverse events in the cupping group were mild
hematomas in three patients at the skin location where
cupping took place, self-limiting light tingling sensations
for a few minutes in the legs after cupping the knee in
two patients, and an increase of chronic lower back pain
in one patient.Discussion
To the best of our knowledge this is the first randomized
trial evaluating the effect of pulsatile dry cupping in OA
of the knee. We observed statistically significant differ-
ences in OA patients who received pulsatile dry cupping
for 4 weeks compared to patients with no intervention
in most of the outcome measures after 4 weeks. Our
results are also of clinical importance: There are various
minimal clinically relevant absolute changes in OA
patients reported in literature: if we consider 9.1 (96%
CI: 10.5; 7.5) on WOMAC as a clinically relevant change
[22], then our results showed a clinical relevant differ-
ences between both treatment groups after 4 weeks.
After 12 weeks (including a no treatment period of
8 weeks in both groups) we still observed significantd means and 95% confidence intervals; adjusted for
1) Control (n = 19) p-value
Mean (95% CI)
42.2 (36.3; 48.1) 0.001
40.2 (33.4; 47.1) 0.004
50.2 (41.2; 59.3) 0.041
42.1 (36.2; 47.9) 0.001
55.0 (46.8; 63.2) 0.005
31.9 (29.2; 34.6) 0.030
52.7 (48.8; 56.6) 0.233
40.8 (34.4; 47.3) 0.032
40.5 (32.1; 48.8) 0.086
47.8 (38.4; 56.1) 0.052
40.3 (33.9; 46.8) 0.031
57.2 (46.3; 68.0) 0.036
30.2 (26.6; 33.9) 0.019
52.6 (48.7; 56.5) 0.831
scores indicate worse condition), VAS = Visual Analogue Scale (0 mm= no pain
ric Quality of Life, (higher scores indicate higher QoL).
Figure 3 WOMAC global score at 4 and 12 weeks per treatment group (adjusted means and 95% confidence intervals; adjusted for
baseline WOMAC global score).
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for pain and stiffness were not significant anymore.
In addition, the results of our trial are of high clinical
interest regarding the low risk of side effects of the treat-
ment compared to common OA treatments, for example,
intra-articular injections of glucocorticosteroids [1].
Due to the exploratory design of our trial, certain lim-
itations have to be considered: We planned an explora-
tory trial without defining a primary outcome parameter
or a formal sample-size calculation – both would be es-
sential in a confirmatory design. Nevertheless, the results
of this trial are robust and most of the outcome param-
eter were statistically significant after 4 and 12 weeks.
Another limitation is that our patients were mainly
recruited through newspaper advertisements and mightFigure 4 Visual Analogue Scale at 4 and 12 weeks per treatment grou
baseline VAS).not be representative for all patients with OA of the
knee. Also, due to the nature of the intervention, a
blinding of patients and study physicians was not pos-
sible. Because patients in the control group received
cupping after 12 weeks of waiting, the long-term effects
of cupping in OA could not be properly assessed. How-
ever, our results suggest that 8 sessions of cupping in
4 weeks still has a relevant effect after 12 weeks. Only
mild side effects were observed, but from a total of only
21 patients in the cupping group, of course only prelim-
inary conclusions can be drawn.
Only a few trials have already evaluated the effective-
ness of cupping in various diseases so far. A trial at the
University of Essen studied the effect of dry traditional
as well as pulsatile dry cupping in chronic neck pain.p (adjusted means and 95% confidence intervals; adjusted for
Figure 5 SF 36 Physical Component Scale at 4 and 12 weeks per treatment group (adjusted means and 95% confidence intervals;
adjusted for baseline).
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cupping compared to waiting-list control were found
after 5 sessions of dry cupping with both methods
[10,11], but also an effect of traditional cupping on pain
and quality of life already after one cupping session has
been observed in this trial [12].
Future studies should aim to assess the optimal fre-
quency and application of cupping. As we combined
cupping on the lower back and knee region, we are not
sure if the cupping of the knee or the lumbosacral area
alone or even sham cupping would be as effective.
To minimize various types of bias, blinded trials are
needed. The development of a special cupping sham de-
vice would be helpful for distinguishing specific from
unspecific or placebo effects and local from non-localFigure 6 SF 36 Mental Component Scale at 4 and 12 weeks per treatm
adjusted for baseline).effects in future studies. The design of our exploratory
study with no intervention control group does not allow
any distinction between specific and unspecific effects of
cupping. Pulsatile cupping itself is already a complex
intervention consisting of cupping, massaging and injur-
ing the local (knee) and distant (lower back) skin areas,
but also other unspecific factors contributing to placebo
effects such as possible relaxing by hearing the rhythmic
pulsations and noises of the cupping device, patient-
practitioner interactions, empathy, therapeutic expecta-
tions and even suggestive effects of the information
sheets may play an important role. Comparing cupping
with other pharmacological or nonpharmacological ther-
apies would be helpful to validate our results and to as-
sess clinical importance and safety.ent group (adjusted means and 95% confidence intervals;
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pathic reflex therapies including massage, acupuncture
cupping and other therapies, Musial et al. [23] summar-
ized three potential mechanisms of actions as hypoth-
esis: Reflex therapies may firstly influence chronic pain
locally by deforming or even injuring the skin which sti-
mulates Aβ fibres in painful but also distal skin regions.
Secondly, the level of the spinal cord may also be
involved: Manipulations may stimulate inhibitory recep-
tive fields of the multi-receptive dorsal horn neurons.
Thirdly, therapeutic effects of the special naturopathic
setting which may have a relaxing and social comforting
effect on the patient and may imitate a “grooming situ-
ation” were discussed. The physiological effects of low-
amplitude oscillation sucking of skin and underlying
tissues have not yet been systematically investigated, but
reproducibility has been demonstrated [5].
From a pragmatic point of view, our results indicate
that pulsatile cupping can be of valuable clinical use and
help for patients with OA of the knee and may therefore
be useful in ambulatory health-care services in addition
to other analgesic treatment e.g. pain medication on
demand.Conclusion
Dry cupping with a pulsatile cupping device relieved
symptoms of patients with osteoarthritis of the knee and
might be a valuable treatment in ambulatory health-care
services in addition to other analgesic treatment e.g. pain
medication on demand. Further confirmatory research
should include a control group receiving sham cupping
to investigate the specific efficacy of cupping.
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